+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Abeta immunization in aged vervet monkeys reduces Abeta levels in brain and CSF

Abeta immunization in aged vervet monkeys reduces Abeta levels in brain and CSF

Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 133 5

Amyloid beta (Abeta) immunization lowers cerebral Abeta in APP tg mice. A recent human clinical trial of Abeta immunization resulted in meningoencephalitis in17/300 AD patients, perhaps due to the recognition of the human Abeta peptide as a self-antigen. Non-human primates have the same Abeta sequence as humans and develop plaques with aging, so we immunized monkeys with Abeta peptide. Five aged (16-25 yr) Caribbean vervet monkeys were given 8 s.c. injections of Abeta peptide with CFA/IFA over 265 days. Baseline and periodic plasma and CSF samples were collected from the 5 immunized monkeys and from 5 aged controls. By Day 42, all immunized monkeys had plasma Abeta titers (e.g., 406 micrograms/ml +- 317 at Day 251) that labeled plaques in human AD and APP tg mouse brain, recognized Abeta1-7, and recognized monomeric and oligomeric Abeta but not full-length APP nor APP C-terminal fragments. Low Abeta titers were observed in CSF as well (e.g., 151 ng/ml +-113 at Day 251). Abetax-40 and Abeta-total levels were elevated in plasma of immunized monkeys. Abetax-40 levels in CSF were decreased by apprx50% at Days 100, 251 and at sacrifice (Day 301). The 4 immunized monkeys and 2 controls were euthanized; frozen brain tissues from 10 age-matched controls were provided. Insoluble AbetaX-42 was decreased 67% (p=0.035) in the immunized animals compared to controls; insoluble Abetax-40 was unchanged. Abeta42-reactive plaques were detected in each of 2 brain regions in 11/13 controls whereas no plaques were detected in any of 6 brain regions examined for each of the 4 immunized vervets. No T cell response or inflammation was found. Thus, Abeta immunization in Vervet monkeys results in anti-Abeta titers, increased peripheral Abeta and decreased CNS Abeta levels, confirming the results observed in APP tg mice for the first time in non-human primates.

(PDF emailed within 1 workday: $29.90)

Accession: 034336968

Download citation: RISBibTeXText

Related references

Abeta IMMUNIZATION IN MONKEYS GENERATES ANTI-Abeta TITERS AND INCREASED PERIPHERAL Abeta LEVELS. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 227 6, 2002

Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. American Journal of Pathology 165(1): 283-297, 2004

Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine 24(15): 2824-2834, 2006

A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. Journal of Neuroscience 28(14): 3555-3566, 2008

Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. Journal of the Neurological Sciences 272(1-2): 87-98, 2008

Abeta immunization: moving Abeta peptide from brain to blood. Proceedings of the National Academy of Sciences of the United States of America 98(16): 8931-8932, 2001

The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiology of Disease 20(2): 541-549, 2005

Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. Journal of Neuroscience 31(6): 2313-2320, 2011

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 98(10): 5856-5861, 2001

The arctic mutation in the Abeta region of APP causes Alzheimers disease with increased Abeta protofibril formation and decreased Abeta peptide levels. Society for Neuroscience Abstracts 26(1-2): Abstract No -587 8, 2000

Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. Journal of Neuroscience 27(32): 8628-8635, 2007

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. Journal of Neuroscience 29(36): 11393-8, 2009

Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Molecular and Cellular Neurosciences 15(2): 183-198, 2000

Passive immunization with an anti abeta antibody rapidly reverses memory impairment but not brain abeta burden in a mouse model of alzheimers disease. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 685 5, 2002

A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta. Current Alzheimer Research 4(3): 297-303, 2007